Gabelli Funds LLC Buys Shares of 22,500 Nevro Corp (NVRO)
Gabelli Funds LLC bought a new position in Nevro Corp (NYSE:NVRO) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 22,500 shares of the medical equipment provider’s stock, valued at approximately $1,553,000.
Several other institutional investors and hedge funds have also recently modified their holdings of NVRO. Hershey Trust Co. bought a new position in shares of Nevro in the 4th quarter worth $119,000. Ameritas Investment Partners Inc. lifted its holdings in shares of Nevro by 17.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,432 shares of the medical equipment provider’s stock worth $181,000 after purchasing an additional 358 shares in the last quarter. PNC Financial Services Group Inc. bought a new position in shares of Nevro in the 2nd quarter worth $190,000. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Nevro in the 3rd quarter worth $211,000. Finally, Sterling Capital Management LLC bought a new position in shares of Nevro in the 2nd quarter worth $233,000.
A number of equities research analysts recently commented on the company. Northland Securities reissued a “buy” rating and issued a $96.00 price target on shares of Nevro in a research report on Tuesday, November 7th. ValuEngine lowered Nevro from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. Leerink Swann reissued an “outperform” rating and issued a $110.00 price target (up from $105.00) on shares of Nevro in a research report on Tuesday, November 7th. Canaccord Genuity lowered their price target on Nevro from $120.00 to $110.00 and set a “buy” rating for the company in a research report on Tuesday, November 7th. Finally, TheStreet raised Nevro from a “d+” rating to a “c-” rating in a research report on Monday, November 6th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $99.25.
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Want to see what other hedge funds are holding NVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nevro Corp (NYSE:NVRO).
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.